<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03257098</url>
  </required_header>
  <id_info>
    <org_study_id>allo-APZ2-CVU-II-01</org_study_id>
    <nct_id>NCT03257098</nct_id>
  </id_info>
  <brief_title>Allogeneic ABCB5-positive Stem Cells for Treatment of CVU</brief_title>
  <official_title>An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Chronic Venous Ulcer (CVU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RHEACELL GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ticeba GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Granzer Regulatory Consulting &amp; Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RHEACELL GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size&#xD;
      reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the&#xD;
      medicinal product to be studied after two applications on the wound surface in patients with&#xD;
      Chronic Venous Ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy&#xD;
      and safety of allogeneic ABCB5-positive mesenchymal stem cells (MSCs) on wound healing in&#xD;
      patients with chronic venous ulcer (CVU). Allogeneic MSCs will be isolated ex vivo and will&#xD;
      be expanded in vitro. The IMP incorporating the ABCB5-positive MSCs will then be applied on&#xD;
      the wound surface of CVU under local anesthesia (on Day 0 and Week 6.1).&#xD;
&#xD;
      Wound measurements from Visit (V) 2 and V9 will be used to determine the cell amount for the&#xD;
      IMP treatments on V3 and V10, respectively.&#xD;
&#xD;
      Patients are followed up for efficacy for 3 months which allows to distinguish actual wound&#xD;
      healing from transient wound coverage.&#xD;
&#xD;
      The wound healing process will be documented by standardized photography. The wound size&#xD;
      evaluation will start on the day of the first change of wound dressing. The quality of the&#xD;
      wound healing process will be assessed on the basis of formation of granulation tissue,&#xD;
      epithelialization and wound exudation.&#xD;
&#xD;
      Pain will be assessed using a numerical rating scale and quality of life will be investigated&#xD;
      with standardized and validated questionnaires. To assess long-term safety of allo-APZ2-CVU&#xD;
      three follow-up visits at Months 6, 9 and 12 after the first IMP applications are included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Interventional, single arm, multicenter, phase I/IIa clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of wound size reduction</measure>
    <time_frame>Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing</time_frame>
    <description>Percentage of wound size reduction at Week 12, or last available post-baseline measurement of Weeks 6, 8 or 10 if the Week 12 measurement is missing (last observation carried forward [LOCF]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse event (AE) occurrence</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>All AEs occurring during the clinical trial will be registered, documented and evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of wound size reduction</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12 (without LOCF);</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute wound size reduction</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving complete wound closure</measure>
    <time_frame>Weeks 2, 3, 4, 6, 8, 10, 12, and at any time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first complete wound closure</measure>
    <time_frame>A priori specification not possible; between baseline and week 12 post baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving 30% wound closure</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, 12, and at any time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first 30% wound closure</measure>
    <time_frame>A priori specification not possible; between baseline and week 12 post baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelialization</measure>
    <time_frame>Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of further wound healing parameters: formation of granulation tissue and wound exudation</measure>
    <time_frame>Visit 3 and Visit 10 before IMP application, Days 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment as per numerical rating scale (NRS)</measure>
    <time_frame>Days 0, 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire</measure>
    <time_frame>Day 0 and Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire</measure>
    <time_frame>Day 0 and Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination and vital signs at Week 6.1 and Week 12</measure>
    <time_frame>Week 6.1 and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Skin Ulcer Venous Stasis Chronic</condition>
  <arm_group>
    <arm_group_label>allo-APZ2-CVU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of IMP on patients wound</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allo-APZ2-CVU</intervention_name>
    <description>Suspension of ABCB5-positive mesenchymal stem cells</description>
    <arm_group_label>allo-APZ2-CVU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged 35 to 85 years;&#xD;
&#xD;
          2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant&#xD;
             ulcer that shows no improvement within 3 months despite of optimal phlebological&#xD;
             therapies or is not healed within 12 months) diagnosed by doppler ultrasonography&#xD;
             (DUS), ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological&#xD;
             review;&#xD;
&#xD;
          3. Wound size of target ulcer between 1.5 and 100 cm2 measured by a standardized&#xD;
             photography at the screening visits (Visit 1 and Visit 2);&#xD;
&#xD;
          4. Wound location below knee;&#xD;
&#xD;
          5. If patients are suffering from 2 or more ulcers at the same extremity, the target&#xD;
             ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from&#xD;
             other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise&#xD;
             at discretion of the investigator; the target ulcer is defined at Visit 1);&#xD;
&#xD;
          6. Body mass index (BMI) between 20 and 45 kg/m²;&#xD;
&#xD;
          7. Patients understand the nature of the procedure and are providing written informed&#xD;
             consent prior to any clinical trial procedure;&#xD;
&#xD;
          8. Women of childbearing potential must have a negative blood pregnancy test at Visit 1&#xD;
&#xD;
          9. Women of childbearing potential and their partner must be willing to use highly&#xD;
             effective contraceptive methods during the course of the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;&#xD;
&#xD;
          2. Current use of systemic steroid medication above Cushing threshold dose (&gt;7.5 mg/d&#xD;
             prednisone or equivalent);&#xD;
&#xD;
          3. Diabetes mellitus that has to be evaluated by blood test (Haemoglobin A1c [HbA1c]&#xD;
             &gt;7.5%);&#xD;
&#xD;
          4. Peripheral Artery Disease (PAD) including claudication with need of treatment;&#xD;
&#xD;
          5. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep&#xD;
             vein thrombosis;&#xD;
&#xD;
          6. Unable to tolerate leg ulcer compression bandage;&#xD;
&#xD;
          7. Infection of the target ulcer requiring treatment as judged clinically;&#xD;
&#xD;
          8. Any chronic dermatological disorders diagnosed at the investigator's discretion;&#xD;
&#xD;
          9. Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;&#xD;
&#xD;
         10. Current use of medications that influence wound healing: systemic immunosuppressives,&#xD;
             cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);&#xD;
&#xD;
         11. Known abuse of alcohol, drugs, or medicinal products;&#xD;
&#xD;
         12. Cancerous or pre-cancerous lesions adjacent to the target wound;&#xD;
&#xD;
         13. Patients anticipated to be unwilling or unable to comply with the requirements of the&#xD;
             protocol;&#xD;
&#xD;
         14. Pregnant or lactating women;&#xD;
&#xD;
         15. Systemic infectious disease diagnosed by serology testing human immunodeficiency virus&#xD;
             (HIV˗1, HIV-2);&#xD;
&#xD;
         16. Any known allergies to components of the IMP;&#xD;
&#xD;
         17. Prior surgical procedures such as bypass or mesh-graft treatment within 2 months prior&#xD;
             to Visit 1;&#xD;
&#xD;
         18. Patients with significant ulcer healing or wound size enlargement of more than 25% at&#xD;
             Visit 2 compared to Visit 1;&#xD;
&#xD;
         19. Treatment of target ulcer with active wound care agents (e.g. iruxol, local&#xD;
             antibiotics or silver dressings), which have not been paused 14 days before IMP&#xD;
             application;&#xD;
&#xD;
         20. Current or previous (within 30 days of enrollment) treatment with another IMP, or&#xD;
             participation and/or under follow-up in another clinical trial;&#xD;
&#xD;
         21. Previous participation in this clinical trial (except for screening failures due to an&#xD;
             inclusion or exclusion criterion);&#xD;
&#xD;
         22. Evidence of any other medical conditions (such as psychiatric illness, physical&#xD;
             examination, or laboratory findings) that may interfere with the planned treatment,&#xD;
             affect the patient's compliance, or place the patient at high risk of complications&#xD;
             related to the treatment;&#xD;
&#xD;
         23. Employees of the sponsor, or employees or relatives of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Kerstan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung</name>
      <address>
        <city>Kiel</city>
        <zip>24119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Venous Ulcer</keyword>
  <keyword>ABCB5</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>varicose ulcer</keyword>
  <keyword>skin ulcer</keyword>
  <keyword>advanced therapy medicinal product</keyword>
  <keyword>somatic cell therapy</keyword>
  <keyword>phase I/IIa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

